The Limits and Breakthroughs of AI in Decoding Human Genome Regulation

More than two decades after the completion of the Human Genome Project, an awkward fact still confronts the scientific community: we know the sequence of nearly all 3 billion base pairs, yet we still cannot explain how the 98% non-coding regions regulate gene expression. As AI large models began pouring into this field, people expected algorithms to unlock the genetic regulatory code in one stroke, just as AlphaFold cracked protein structure. The reality is far more complex—the multi-layered physical mechanisms of genome regulation are precisely the blind spot of current AI foundation models.

From "Junk DNA" to Regulatory Dark Matter: A Rewritten History of Understanding

When Watson and Crick revealed the double helix structure in 1953, the scientific community imagined the genome as a tidy instruction manual for life. The sequencing results of the Human Genome Project from 1990 to 2003, however, gave a counterintuitive answer: only about 2% of the sequence encodes proteins, and the remaining roughly 98% was once carelessly called "junk DNA."

In the post-genomic era, high-throughput technologies such as ChIP-seq and ATAC-seq revealed that this 98% non-coding sequence is not useless—it constitutes a vast regulatory landscape from promoters to enhancers, determining when, where, and how strongly genes are expressed. Deciphering this regulatory "dark matter" is crucial for understanding disease-associated variants, designing gene therapies, and predicting drug responses. The problem is that its combinatorial complexity far exceeds the capability boundary of any single computational method.

Human Gene Regulation: A Symphony Far More Precise Than Bacteria

Transcription Factors: From Simple Switches to Orchestra Members

In bacteria, a single transcription factor often acts like a key fitting a lock, controlling gene switches with OR logic. The behavior of human transcription factors is closer to orchestra members:

• Low specificity—recognizing short and degenerate motifs, many transcription factors can bind similar sites
• Combinatorial binding—often operating as pairs or larger complexes, integrating multiple signals
• Context dependence—the same transcription factor can be an activator in one cell type and a repressor in another

Karen Adelman of Harvard Medical School put it incisively: "Our genome is not designed sitting at a drawing board." The regulatory code is emergent, not predetermined.

Enhancers: The Numerical Dilemma of a Distributed Switchboard

Enhancers are DNA segments that recruit transcription factors and transmit "start" signals to promoters, with action distances reaching millions of nucleotides. They have three properties that give computational models headaches: their numbers range from hundreds of thousands to over a million, far exceeding the roughly 20,000 protein-coding genes; one enhancer can regulate multiple genes, and one gene is controlled by dozens of enhancers; activation requires precise combinations of transcription factors, causing the same enhancer to behave completely differently in different tissues.

Wendy Bickmore of the University of Edinburgh was blunt about the field's predicament: "Embarrassingly, 25 years after the Human Genome Project, we still don't know the locations of all enhancers in the genome, let alone what they do when they function or which genes they control."

Enhancers usually do not encode proteins; instead, they consist of DNA sequences of hundreds of base pairs containing clusters of multiple transcription factor binding motifs. Their transcriptional activity through "enhancer RNA" (eRNA) is often used as an activity marker, and they can also be annotated genome-wide through chromatin accessibility and histone modifications (such as H3K27ac and H3K4me1). Projects such as ENCODE and Roadmap Epigenomics have systematically mapped candidate enhancer atlases across hundreds of cell types, but epigenetic features alone can only mark "candidates"—they cannot determine the true target genes or functional necessity, which is another side of the numerical dilemma.

Chromatin Loops and Cohesin Extrusion: Three-Dimensional Physics Is the Core

Distal enhancers contact target promoters through chromatin loops. The motor protein cohesin extrudes along DNA to form dynamic loops, building transcriptional "hubs." These hubs are not rigid scaffolds but liquid condensates—regulatory proteins concentrate here, enabling cells to respond quickly to environmental signals. Super-resolution microscopy studies have observed these foci assembling and dissipating within minutes.

Hi-C and derived technologies convert spatially contacting DNA fragments into genome-wide contact frequency maps through formaldehyde crosslinking, restriction enzyme digestion, and proximity ligation, with resolution down to the kilobase level. The loop extrusion model holds that cohesin rings extrude along DNA at about 0.5-1 kb per second until they stall at correctly oriented CTCF binding sites, thereby forming stable loops within topologically associating domains (TADs). TAD boundaries are typically enriched for CTCF and active transcription marks; boundary disruption can lead to abnormal enhancer-oncogene contacts and is one of the pathogenic mechanisms in multiple leukemias and solid tumors.

The Current State of AI Genomic Foundation Models: Strong at Correlation Mining, Weak at Mechanistic Explanation

The Rise of Foundation Models

In recent years, large-scale genomic foundation models such as Evo 2, Genos, and Google DeepMind's Alpha Genome have emerged, trained on petabytes of sequence, epigenomic marks, and phenotype association data. They can predict the impact of single-nucleotide variants on disease risk, infer tissue-specific expression patterns from raw DNA, and recommend candidate regulatory elements based on sequence motifs. At the level of correlation mining, these models have indeed achieved a scale beyond human reach.

Genomic foundation models typically adopt the Transformer architecture, tokenizing DNA sequences into k-mer tokens and pre-training on trillions of bases through masked language modeling or next-token prediction. The Evo series goes further by introducing long context windows during training to capture long-range dependencies across hundreds of thousands of bases and supporting zero-shot variant effect prediction. However, the learning objective of such models is essentially statistical optimization of sequence completion, not explicit encoding of physical or causal mechanisms; the larger the model capacity, the more easily it perfectly fits within the training distribution while failing out of distribution—this is also the architectural root of the "triple black-box limitations."

The Triple Limitations of the Black Box

However, correlation is not causation. Current models have three structural problems:

• Lack of mechanistic insight—unable to explain why a variant alters transcription factor binding or chromatin looping
• Opaque decision pathways—gradient-based attribution methods produce noisy importance scores that are sometimes even misleading
• Overfitting risk—training on biased datasets (such as cell lines overrepresenting certain tissues) may produce spurious predictions when transferred to primary human samples

In practice, researchers may obtain a high-confidence prediction—that a non-coding variant disrupts an enhancer—yet be unable to offer any mechanistic hypothesis to design follow-up experiments. In clinical genomics settings where mechanistic validation is a regulatory hard requirement, this directly limits translational value.

This predicament echoes lessons from AI deployment in security. Zoom was once forced to urgently patch an AI prompt injection vulnerability that exposed how black-box models can be manipulated (according to analysis by the tech blog LTDeveloper), and the AI-enhanced antivirus solution Intego on macOS similarly faces tension between rapid threat detection and interpretability. Genomic AI faces the same class of problem: the more capable, the harder to explain.

Why This Matters for the Triple Fate of Science, Clinical Practice, and Industry

An Accelerator or Stumbling Block for Disease Gene Discovery

Accurate regulatory annotation can transform "variants of uncertain significance" into clinically actionable findings. Misjudging regulatory variants directly impedes rare disease diagnosis—many pathogenic mutations lie outside coding regions—and also affects pharmacogenomics, because gene expression variability directly relates to drug metabolism and efficacy.

A Navigator for Therapeutic Development

CRISPR therapies rely on precise knowledge of enhancer-gene connections to avoid off-target effects. AI models that predict only correlations may recommend editing strategies that disrupt critical chromatin loops, bringing unforeseen toxicity.

Capital Allocation in the Biotechnology Market

Biotech companies are investing heavily in AI-assisted drug target identification. Overreliance on opaque models can lead to misallocation of R&D funds, flooding pipelines with targets lacking mechanistic validation. Transparent, mechanistic AI can improve risk-adjusted return on investment—a core metric for genomics venture capital. Regulators such as the FDA and EMA increasingly require mechanistic justification for AI-driven diagnostics; black-box predictions without interpretability may encounter regulatory roadblocks, delaying market entry and patient access.

Paths Toward Mechanistic, Interpretable Genomic AI

Physics-Aware Neural Networks

Researchers are embedding chromatin polymer physics simulations into deep learning pipelines. By penalizing predictions that violate known constraints (such as the maximum loop size determined by cohesin processivity), hybrid models can produce enhancer-gene maps consistent with underlying mechanical laws.

Causal Perturbation Data as Supervisory Signals

Large-scale CRISPRi/a screens can now systematically perturb thousands of putative regulatory elements across dozens of cell types. Training models on these perturbation data is a key path to distinguishing correlation from causation.

CRISPRi (CRISPR interference) uses catalytically dead Cas9 (dCas9) fused to the KRAB repression domain to reversibly silence target regulatory elements without cutting DNA; CRISPRa instead fuses activation domains to achieve upregulation. Perturb-seq combines pooled perturbations with single-cell RNA sequencing, enabling simultaneous readout of the transcriptome effects of thousands of perturbations and thereby constructing "perturbation-expression" causal maps. The unique value of such data lies in directly measuring phenotypic changes after intervention, providing models with supervisory signals that distinguish "correlation" from "necessity" and compensating for the fundamental flaw of purely observational data.

Multimodal Data Integration and Community Benchmarks

Combining single-cell ATAC-seq, Hi-C, CUT&RUN, and spatial transcriptomics can provide richer context for AI models. Open benchmarks similar to the CASP competition in protein folding can standardize evaluation of regulatory prediction models, and transparent leaderboards will incentivize models to pursue interpretability beyond accuracy.

Conclusion: The Structural Blind Spot of Flat String Models

Current genomic foundation models treat the genome as a flat string, extracting statistical patterns from massive alignment and epigenomic data. They can mark regions that "look like" enhancers but do not explicitly model three key processes: the stochastic dynamics of cohesin- and CTCF-driven loop extrusion, the biophysical principles of phase-separated condensate formation, and the cell-type-specific grammar of transcription factor cooperation. These processes are governed by physics and chemistry rather than pure sequence statistics—models that learn only correlations are doomed to miss the key causal chain.

This article is compiled and adapted from the original analysis "Why AI Isn't Ready to Tackle Our Convoluted Genomes" on the LTDeveloper blog.